Patients
Lenabasum
Multi-system Inflammatory
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Launch |
|---|---|---|---|---|
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 3 Phase in progress
|
Launch Phase not started
|
Targeting 2021 launch
Multi-system Inflammatory
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Launch |
|---|---|---|---|---|
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 3 Phase in progress
|
Launch Phase not started
|
Multi-system Inflammatory
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Launch |
|---|---|---|---|---|
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
Launch Phase not started
|
Genetic
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Launch |
|---|---|---|---|---|
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
Launch Phase not started
|
CRB-4001
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Launch |
|---|---|---|---|---|
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Launch Phase not started
|
Scheduled to Enter Phase 1 in 2019, NIH Committed to Funding Phase 2 Study.
Preclinical library (more than 600 compounds)
Goal: 1-2 new Phase 1 programs per year starting in 2020
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Launch |
|---|---|---|---|---|
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Launch Phase not started
|
Lenabasum is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
To learn more about each of our ongoing studies, please click on one of the below links.